Centrally Administered Cortistation-14 Induces Antidepressant-Like Effects in Mice Via Mediating Ghrelin and GABA Receptor Signaling Pathway
Overview
Affiliations
Cortistatin-14 (CST-14), a recently discovered cyclic neuropeptide, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor to exert its biological activities and co-exists with GABA within the cortex and hippocampus. However, the role of CST-14 in the control of depression processes is not still clarified. Here, we tested the behavioral effects of CST-14 in the in a variety of classical rodent models of depression [forced swimming test (FST), tail suspension test (TST) and novelty-suppressed feeding test]. In the models of depression, CST-14 produced antidepressant-like effects, and does not altered locomotor activity levels. And, we found that CST-14 mRNA and BDNF mRNA were significantly decreased in the hippocampus and cortex after mice exposed to stress. Further data show that i.c.v. administration of CST-14 produce rapid antidepressant effects, and does not altered locomotor activity levels. Then these antidepressant-like effects were significantly reversed by [D-Lys]GHRP-6 (ghrelin receptor antagonist), but not c-SOM (SSTRs antagonist). Meanwhile, the effects of some neurotransmitter blockers indicates that only GABA system, but not CRF1 receptor, α/β-adrenergic receptor, is involved in the antidepressant effect of CST-14. The effects of the mTOR inhibitor (rapamycin), the PI3K inhibitor (LY294002) and the p-ERK1/2 inhibitor (U0126) suggesting that the ERK/mTOR or PI3K/Akt/mTOR signaling pathway is not involved in the antidepressant effects of CST-14. Interestingly, intranasal administration of CST-14 led to reducing depressive-like behavior, and near-infrared fluorescent experiments showed the real-time bio-distribution in brain after intranasal infusion of Cy7.5-CST-14. Taken all together, the results of present study point to a role for CST-14 in the modulation of depression processes via the ghrelin and GABA receptor, and suggest cortistation may represent a novel strategy for the treatment of depression disorders. -CST-14 and BDNF mRNA are decreased in hippocampus and cortex once mice exposed to stress.-i.c.v. or intranasal administration of CST-14 produce rapid antidepressant effects.-NIR fluorescence imaging detected the brain uptake and distribution after intranasal CST-14.-Antidepressant effects of CST-14 were only related to ghrelin and GABA system.-Co-injection of CST-14 and NPS produce antidepressant effect, and do not impair memory.
Hohoff C, Kerkenberg N, Zhang M, Palkowska W, Wachsmuth L, Peng M Transl Psychiatry. 2025; 15(1):20.
PMID: 39856044 PMC: 11759705. DOI: 10.1038/s41398-025-03240-7.
Cortistatin as a Novel Multimodal Therapy for the Treatment of Parkinson's Disease.
Serrano-Martinez I, Pedreno M, Castillo-Gonzalez J, Ferraz-de-Paula V, Vargas-Rodriguez P, Forte-Lago I Int J Mol Sci. 2024; 25(2).
PMID: 38255772 PMC: 10815070. DOI: 10.3390/ijms25020694.
Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients.
Jin Z, Han Y, Zhang D, Li Z, Jing Y, Hu B Pharmaceutics. 2022; 14(10).
PMID: 36297505 PMC: 9611373. DOI: 10.3390/pharmaceutics14102070.
MMI-0100 Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice through Targeting MK2 Pathway.
Wang Z, Liang X, Chang X, Nie Y, Guo C, Jiang J Molecules. 2019; 24(15).
PMID: 31382637 PMC: 6696270. DOI: 10.3390/molecules24152832.